Resverlogix Corp. (RVX.TO) TSX
0.10
+0.005(+5.26%)
Currency In CAD
- General
- Statistics
- Historical Data
- Profile
- Financials
0.10
+0.005(+5.26%)
Currency In CAD
Address
4820 Richard Road SW
Calgary, AB T3E 6L1
Canada
Phone
14032549252
Website
Sector
Healthcare
Industry
Biotechnology
Employees
19
First IPO Date
May 07, 2004
| Name | Title | Pay | Year Born |
| Donald J. McCaffrey | Co-Founder, Chairman, President, Chief Executive Officer & Secretary | 505,200 | N/A |
| Ewelina Kulikowski | Chief Scientific Officer | 250,000 | N/A |
| Aaron Bradley Cann | Chief Financial Officer | 281,800 | N/A |
| Michael Sweeney | Senior Vice President of Clinical Development | 538,703 | 1961 |
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada. The company is headquartered in Calgary, Canada.